ISSN: 0741-238X
Journal Home
Journal Guideline
Advances in Therapy Q1 Unclaimed
Advances in Therapy is a journal indexed in SJR in Medicine (miscellaneous) and Pharmacology (medical) with an H index of 83. It has a price of 3190 €. It has an SJR impact factor of 1,089 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,089.
Advances in Therapy focuses its scope in these topics and keywords: patients, treatment, management, study, editor, current, retrospective, clinical, letter, lumbar, ...
Type: Journal
Type of Copyright:
Languages: English
Open Access Policy: Open Choice
Type of publications:
Publication frecuency: -
3190 €
Inmediate OANPD
Embargoed OA0 €
Non OAMetrics
1,089
SJR Impact factor83
H Index347
Total Docs (Last Year)1113
Total Docs (3 years)13832
Total Refs4296
Total Cites (3 years)1039
Citable Docs (3 years)3.4
Cites/Doc (2 years)39.86
Ref/DocOther journals with similar parameters
Nature Biomedical Engineering Q1
Journal of Thoracic Oncology Q1
Annual Review of Clinical Psychology Q1
Lancet Digital Health, The Q1
Journal of Experimental Medicine Q1
Compare this journals
Aims and Scope
Best articles by citations
Effects of different postmenopausal hormone therapy regimens on cerebral blood flow and cognitive functions
View moreRandomized Trial of Brinzolamide/Brimonidine Versus Brinzolamide Plus Brimonidine for Open-Angle Glaucoma or Ocular Hypertension
View morePreservation of Anemia Control and Weekly ESA Dosage After Conversion from PEG-Epoetin Beta to Darbepoetin Alfa in Adult Hemodialysis Patients: The TRANSFORM Study
View moreMutations in the epidermal growth factor receptor gene in non-small cell lung cancer: Impact on treatment beyond gefitinib and erlotinib
View moreIvabradine and Bisoprolol on Doppler-derived Coronary Flow Velocity Reserve in Patients with Stable Coronary Artery Disease: Beyond the Heart Rate
View moreA real-world study of patients with type 2 diabetes initiating basal insulins via disposable pens
View moreEfficacy and Safety of Fingolimod in Hispanic Patients with Multiple Sclerosis: Pooled Clinical Trial Analyses
View moreEfficacy of Triamcinolone Acetonide Extended-Release in Participants with Unilateral Knee Osteoarthritis: A Post Hoc Analysis
View moreTotally implantable venous access devices via subclavian vein: A retrospective study of 368 oncology patients
View moreThe effect of rapid blood pressure control on P-wave dispersion in hypertensive urgency
View moreReview of the If selective channel inhibitor ivabradine in the treatment of chronic stable angina
View moreAdjunctive Agents for Cervical Preparation in Second Trimester Surgical Abortion
View moreAdvances in Clinical Cardiology
View moreCost-Utility of First-Line Actinic Keratosis Treatments in Finland
View moreRelease of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels
View moreImproved Response Rates with Bortezomib in Relapsed or Refractory Multiple Myeloma: An Observational Study in Chinese Patients
View moreA Pharmacokinetic Bioequivalence Study Comparing Pirfenidone Tablet and Capsule Dosage Forms in Healthy Adult Volunteers
View moreTestosterone treatment in elderly men
View moreSix-Month Outcomes of Goniotomy Performed with the Kahook Dual Blade as a Stand-Alone Glaucoma Procedure
View morePharmacoeconomics of Granulocyte Colony-Stimulating Factor: A Critical Review
View moreThe platinum chromium element stent platform: from alloy, to design, to clinical practice
View moreEconomic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs
View moreA phase 3, randomized, placebo-controlled trial of DepoFoam® bupivacaine (extended-release bupivacaine local analgesic) in bunionectomy
View moreIntragastric Balloon Treatment for Obesity: FDA Safety Updates
View more
Comments